A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity

Nature Immunology

Volumn 17, Issue 5, 2016, Pages 523-530

  Chan, Ying Kai ^a   Gack, Michaela U ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 3 3 EPSILON PROTEIN; ADAPTOR PROTEIN; ARGININE; ASPARTIC ACID; LEUCINE; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MITOCHONDRIAL PROTEIN; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; PROLINE; PROTEIN 14 3 3; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; NS3 PROTEASE, DENGUE VIRUS; SERINE PROTEINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VISA PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; DENGUE VIRUS 2; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION; AMINO ACID SEQUENCE; CELL CULTURE; CELL LINE; CONFOCAL MICROSCOPY; GENETICS; HEK293 CELL LINE; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

14-3-3 PROTEINS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DEAD BOX PROTEIN 58; DEAD-BOX RNA HELICASES; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOBLOTTING; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; RNA INTERFERENCE; SEQUENCE HOMOLOGY, AMINO ACID; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84961392938     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3393     Document Type: Article

References (45)

1. Villar, L. et al. Efficacy of a tetravalent Dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113-123 (2015).
2. Capeding, M.R., et al., CYD14 Study Group Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358-1365 (2014).
3. Takeuchi, O., Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
4. Goubau, D., Deddouche, S., Reis e Sousa, C. Cytosolic sensing of viruses. Immunity 38, 855-869 (2013).
5. Loo, Y.M., Gale, M. Jr. Immune signaling by RIG-I-like receptors. Immunity 34, 680-692 (2011).
6. Goubau, D. et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5?-diphosphates. Nature 514, 372-375 (2014).
7. Gack, M.U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916-920 (2007).
8. Peisley, A., Wu, B., Xu, H., Chen, Z.J., Hur, S. Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature 509, 110-114 (2014).
9. Zeng, W. et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 141, 315-330 (2010).
10. Dixit, E. et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141, 668-681 (2010).
11. Horner, S.M., Liu, H.M., Park, H.S., Briley, J., Gale, M. Jr. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc. Natl. Acad. Sci. USA 108, 14590-14595 (2011).
12. Seth, R.B., Sun, L., Ea, C.K., Chen, Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669-682 (2005).
13. Schneider, W.M., Chevillotte, M.D., Rice, C.M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513-545 (2014).
14. Belgnaoui, S.M., Paz, S., Hiscott, J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr. Opin. Immunol. 23, 564-572 (2011).
15. Liu, H.M. et al. The mitochondrial targeting chaperone 14-3-3ϵ regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 11, 528-537 (2012).
16. Schmid, M.A., Diamond, M.S., Harris, E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front. Immunol. 5, 647 (2014).
17. Green, A.M., Beatty, P.R., Hadjilaou, A., Harris, E. Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426, 1148-1160 (2014).
18. Ashour, J., Laurent-Rolle, M., Shi, P.Y., Garciá-Sastre, A. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83, 5408-5418 (2009).
19. Aguirre, S. et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog. 8, e1002934 (2012).
20. Yu, C.Y. et al. Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog. 8, e1002780 (2012).
21. Apte-Sengupta, S., Sirohi, D., Kuhn, R.J. Coupling of replication and assembly in flaviviruses. Curr. Opin. Virol. 9, 134-142 (2014).
22. Miller, S., Kastner, S., Krijnse-Locker, J., Bühler, S., Bartenschlager, R. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J. Biol. Chem. 282, 8873-8882 (2007).
23. Li, X.D., Sun, L., Seth, R.B., Pineda, G., Chen, Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 102, 17717-17722 (2005).
24. Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
25. Khumthong, R., Angsuthanasombat, C., Panyim, S., Katzenmeier, G. In vitro determination of dengue virus type 2 NS2B-NS3 protease activity with fluorescent peptide substrates. J. Biochem. Mol. Biol. 35, 206-212 (2002).
26. Falgout, B., Pethel, M., Zhang, Y.M., Lai, C.J. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65, 2467-2475 (1991).
27. Mhawech, P. 14-3-3 proteins-an update. Cell Res. 15, 228-236 (2005).
28. Yaffe, M.B. et al. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91, 961-971 (1997).
29. Luo, D. et al. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82, 173-183 (2008).
30. Kinney, R.M. et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230, 300-308 (1997).
31. Butrapet, S. et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J. Virol. 74, 3011-3019 (2000).
32. Desmyter, J., Melnick, J.L., Rawls, W.E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 2, 955-961 (1968).
33. Gack, M.U. et al. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc. Natl. Acad. Sci. USA 105, 16743-16748 (2008).
34. Sumpter, R. Jr. et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689-2699 (2005).
35. Jessie, K., Fong, M.Y., Devi, S., Lam, S.K., Wong, K.T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189, 1411-1418 (2004).
36. Rodriguez-Madoz, J.R., Bernal-Rubio, D., Kaminski, D., Boyd, K., Fernandez-Sesma, A. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J. Virol. 84, 4845-4850 (2010).
37. Petosa, C. et al. 14-3-3zeta binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J. Biol. Chem. 273, 16305-16310 (1998).
38. Shapira, S.D. et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 139, 1255-1267 (2009).
39. Chan, Y.K., Huang, I.C., Farzan, M. IFITM proteins restrict antibody-dependent enhancement of dengue virus infection. PLoS One 7, e34508 (2012).
40. Urano, T. et al. Efp targets 14-3-3? for proteolysis and promotes breast tumour growth. Nature 417, 871-875 (2002).
41. Wies, E. et al. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 38, 437-449 (2013).
42. Lin, R., Génin, P., Mamane, Y., Hiscott, J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20, 6342-6353 (2000).
43. Hatzivassiliou, E., Cardot, P., Zannis, V.I., Mitsialis, S.A. Ultraspiracle, a Drosophila retinoic X receptor alpha homologue, can mobilize the human thyroid hormone receptor to transactivate a human promoter. Biochemistry 36, 9221-9231 (1997).
44. Diamond, M.S., Edgil, D., Roberts, T.G., Lu, B., Harris, E. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J. Virol. 74, 7814-7823 (2000).
45. Lambeth, C.R., White, L.J., Johnston, R.E., de Silva, A.M. Flow cytometry-based assay for titrating dengue virus. J. Clin. Microbiol. 43, 3267-3272 (2005).